r Ivermectin (IVM) is a widely used antiparasitic drug in humans and pets which activates glutamate-gated Cl − channel in parasites.
Introduction
Ivermectin (IVM) is a well-known and commonly used antiparasitic drug which was discovered and modified by Drs Omura and Campbell (Campbell et al. 1983; Ikeda et al. 1987) . IVM kills parasite by increasing the activity of glutamate-gated Cl − channels at nanomolar concentrations and this results in the hyperpolarization of the nerve and muscle cells of parasite (Cully et al. 1996; Martin, 1996; Burkhart, 2000) . IVM also targets several Cys-loop receptors of ligand-gated channels, including the glycine receptor, GABA A R, α7 nicotinic acetylcholine receptor and histamine receptor (Sigel & Baur, 1987; Krause et al. 1998; Adelsberger et al. 2000; Shan et al. 2001; Zheng et al. 2002) . The P2X 4 receptor and farnesoid X receptor are also activated by IVM (Silberberg et al. 2007; Jin et al. 2013) . Previous studies demonstrated that IVM modulates channel function by inserting deeply into subunit interfaces on the transmembrane domains (TMs) of these Cys-loop receptors and the P2X 4 receptor, and that the IVM-binding site is near the extracellular membrane surface (Silberberg et al. 2007; Jelinkova et al. 2008; Lynagh & Lynch, 2012) .
In the course of screening of a small-molecule library towards the identification of modulators of a G i/o -coupled orphan G-protein-coupled receptor (GPCR) by monitoring G-protein-gated inwardly rectifying K + (GIRK) current, we happened to observe that IVM activates GIRK channels even in the absence of the orphan GPCR. The GIRK family has four members: Kir3.1 (GIRK1), Kir3.2 (GIRK2), Kir3.3 (GIRK3) and Kir3.4 (GIRK4) . Most of the GIRK channels are heterotetramers in native tissues, especially Kir3.1-Kir 3.2 in the brain and Kir3.1-Kir 3.4 in the heart, and these channels control the excitability of neurons and the rate of heart beat, respectively (Noma & Trautwein, 1978; Kubo et al. 1993; Lesage et al. 1994; Krapivinsky et al. 1995; Liao et al. 1996; Inanobe et al. 1999; Hibino et al. 2010) . GIRK channels are directly activated by G βγ subunits when G i/o -coupled GPCR on the membrane of the same cell is activated by agonists, which results in the dissociation of G βγ from G α (Logothetis et al. 1987; Ito et al. 1992; Clapham & Neer, 1993; Reuveny et al. 1994) . The channel activity is also known to be directly modulated by phosphatidylinositol 4,5-bisphosphate (PIP 2 ) and intracellular Na + (Huang et al. 1998; Sui et al. 1998; Ho & Murrell-Lagnado, 1999) , and activated by some chemicals, including alcohols, dithiothreitol, narigin and ML297 (GIRK1 only) (Kobayashi et al. 1999; Lewohl et al. 1999; Zeidner et al. 2001; Aryal et al. 2009; Yow et al. 2011; Kaufmann et al. 2013) .
Since the mechanism of IVM-mediated GIRK activation is unclear, we aimed to clarify the structural background and action mode of IVM on the GIRK channel function. In the present study, we demonstrate that IVM activates Kir3.1-Kir3.2 (including native GIRK in hippocampal neurons) strongly and Kir3.1-Kir3.4 weakly, in a PIP 2 -dependent manner, and we reveal a unique mode of action of IVM on GIRK channels unlike its mode of action on Cys-loop and P2X 4 receptors. We observed that the slide helix between TM1 and the N-terminal cytoplasmic tail domain (CTD), rather than the TMs of the GIRK channel, acts as a primarily structural determinant for IVM-mediated activation. Our results present strong evidence indicating that IVM possesses higher efficacy of activation of Kir3.2 than Kir3.4, and that a unique amino acid residue located in the slide helix at the TM-CTD interfaces of Kir3.2, Ile82, plays a critical role for activation by IVM.
Methods

Ethical approval
All experiments were approved by the Animal Care Committee of the National Institutes of Natural Sciences (an umbrella institution of National Institute for Physiological Sciences, Japan), and were performed in accordance with its guidelines. The animal experiments also comply with the policy and regulations of The Journal of Physiology (Grundy, 2015) .
cDNA and molecular biology
The cRNA of rat Kir3.1, mouse Kir3.2, mouse Kir3.3, rat Kir3.4, mouse Kir2.1, porcine M2R and Ci-VSP were used in this study. The Ci-VSP cDNA was kindly provided by Dr Yasushi Okamura (Osaka University, Osaka, Japan). Mutations in Kir3.2 and Kir3.4 were introduced using the PfuUltra II Fusion HS DNA Polymerase kit (Agilent Technologies, Santa Clara, CA, USA) and verified by DNA sequencing. Complementary RNAs were transcribed from the linearized cDNA by mMessage mMachine kit (Ambion). and housed in the institutional aquatic facility. The total number of frogs for obtaining oocytes in the present study was about 30. Ten to fifteen frogs at a time were maintained in a water tank with sufficient space (L900 × W660 × H500 mm) and normal feeding at 18°C on a light-dark cycle of 12 h light and 12 h dark. Frogs were anaesthetized by 0.15% tricaine for 30 min through skin absorption in a separated water box. Oocytes were then surgically removed from the frogs by making a small incision on the abdomen on ice. The depth of anaesthesia was monitored by the disappearance of withdrawal reflexes. After surgery, frogs recovered from anaesthesia and were then returned to another water tank. Post-operational frogs did not show signs of distress and recuperated for at least 3 months before the next surgery. After emptying of oocytes, anaesthetized frogs were killed by double pithing. Oocytes were treated with collagenase (2 mg ml -1 , Sigma-Aldrich) for 3-4 h to remove the follicular membrane before injection with 50 nl of cRNA. Injected oocytes were incubated at 17°C in frog Ringer solution containing: 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO 3 , 0.3 mM Ca(NO 3 ) 2 , 0.41 mM CaCl 2 , 0.82 mM MgSO 4 and 15 mM Hepes (pH 7.6) with penicillin-streptomycin solution (0.1%, Sigma-Aldrich). Oocytes for single-channel recording were incubated in a hypertonic solution (a double concentration of frog Ringer solution) for 10 min to manually remove the vitelline membrane by forceps. Currents were recorded 2-4 days after the cRNA injection. Oocytes used in some experiments were pretreated with pertussis toxin (PTX) by injection of 3.25 ng PTX 12 h before electrophysiological recording.
Electrophysiological recording of oocytes
Membrane currents were recorded by two-electrode voltage clamp using an OC-725C amplifier (Warner Instruments) at room temperature (22-25°C). The bath solution contained: 96 mM KCl, 3 mM MgCl 2 and 5 mM Hepes (pH 7.5 with KOH). In some experiments, ND96 was used as bath solution, which contained: 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 and 5 mM Hepes (pH 7.5 with NaOH). The resistance of glass electrodes was 0.2-0.5 M when filled with the pipette solution containing 3 M potassium acetate and 10 mM KCl. Data acquisition was performed by a digital converter (Digidata 1440, Molecular Devices) and pCLAMP 10.5 software (Molecular Devices). The dose-dependent response of IVM was measured by sequential application of IVM to the bath solution using an electronic adjustable pipette C5000 (Gilson; 1 ml s −1 ) and washed out using a perfusion system (1 ml 15 s −1 ) for inlet and suction pipettes with negative pressure at the outlet. The EC 50 and dose-response curve were calculated by fitting data to the Hill equation with SigmaPlot 13 (Hulinks): y = min + (max -min)/(1 + (x/EC 50 )ˆ(-Hill slope)), where x refers to the IVM concentration, y refers to the normalized response (I IVM /I Basal ; see detail in Fig. 1 and Results) at a given concentration, 'max' refers to the maximum response, 'min' refers to the minimum response, EC 50 is the concentration of agonist generating half-maximal response and 'Hill slope' is the slope.
Single channel currents were recorded using the cell-attached patch clamp configuration (Axopatch 200B, Molecular Devices) at room temperature, and the current traces were low-pass filtered at 2 kHz. The bath and pipette solution contained: 96 mM KCl, 3 mM MgCl 2 and 5 mM Hepes (pH 7.4 with KOH). The resistance of the glass electrodes was 2-5 M when filled with the pipette solution. Data acquisition was performed using a digital converter (Digidata 1440) and pCLAMP 10. 
Primary culture of rat hippocampal neurons
Primary cultures of rat hippocampal neurons were prepared basically as described previously (Fukata et al. 2013) . Pregnant Wistar/ST rats were purchased from Japan SLC, Inc. (Hamamatsu, Japan) and used on the day the rats were received. A pregnant rat with embryonic rats (embryonic days 19) was killed by CO 2 inhalation (two rats in total) and then embryos (10 embryos per pregnant rat) were removed and decapitated. Hippocampi were dissected from embryonic rat brain and placed in a 10 cm dish on ice with a Ca 2+ -and Mg 2+ -free Hanks-buffered saline (CMF-HBSS) containing: Hanks' Balanced Salt solution (Sigma-Aldrich), 10 mM glucose, 10 mM Hepes (pH 7.3 with NaOH). To dissociate hippocampal neurons, hippocampi were treated with 10 units ml −1 papain (Worthington Biochemical) for 10 min at 37°C. Dissociated neurons were plated onto 12 mm poly-L-lysine (Sigma-Aldrich)-coated glass coverslips in 24-well plates (3 × 10 4 cells well −1 ) with a plating medium containing: neurobasal medium (ThermoFisher Scientific), 10% FBS and 10 mM Hepes (pH 7.3 with NaOH). Neurons were incubated at 37°C and 5% CO 2 for 3 h, and then the medium was replaced by a medium containing: neurobasal medium, B-27 supplement (ThermoFisher Scientific), 2 mM GlutaMax supplement-I (ThermoFisher Scientific) and 10 mM Hepes (pH 7.3 with NaOH). Half of the medium was removed and replaced with fresh medium every 7 days. After 13-16 days in culture, neurons were used for electrophysiological recordings. containing: 120 mM NaCl, 25 mM KCl, 3 mM MgCl 2 , 5.5 mM D-glucose and 5 mM Hepes (pH 7.4 with NaOH), supplemented with 1 μM tetrodotoxin (TTX, Wako, Osaka, Japan) and 10 μM ZD7288 (Abcam, a blocker of hyperpolarization-activated cation current (I h )). Data acquisition was performed using a digital converter (Digidata 1322) and pCLAMP 9.2 software (Molecular Devices). IVM and a GIRK channel blocker, tertiapin-Q (TPN-Q, Abcam), were applied to the Ca 2+ -free high K + bath solution and perfused to the recording chamber using VC-8 valve controller (Warner Instruments) and SF-77B perfusion fast-step (Warner Instruments).
Chemicals
In the initial screening to search for modulator(s) of an orphan G i/o -coupled GPCR, a small-molecule library in the laboratory of one of the authors (M. U.) was used.
Other chemicals were purchased from Sigma-Aldrich. IVM was dissolved in DMSO by sonication; abamectin (ABM), doramectin (DOM) and eprinomectin (EPM) were dissolved in ethanol. Application of chemicals in experiments were diluted to a final solvent concentration <0.1% in the bath solution, which elicited a negligible effect on GIRK channel.
Data analysis and statistics
Data were analysed by Clampfit 10.5 (Molecular Devices) and SigmaPlot 13 (Hulinks). All data are shown as means ± SD from n cells. Statistical differences were evaluated using one-way ANOVA and Dunnett's or Dunn's multiple comparison tests, comparing every group with the control group. A Student's paired t test was used to evaluate the statistical difference between the IVM-induced current before and after application of TPN-Q in neurons. Values of P < 0.05 were judged to be statistically significant.
Results
IVM activates GIRK current in Xenopus oocytes
Through heterologous expression of GIRK heteromeric complexes, Kir3.1-Kir3.2 or Kir3.1-Kir3.4, in Xenopus oocytes, we observed electrophysiologically that application of IVM (0.1-100 μM) induced an increase in inward current at -100 mV ( Fig. 1A-C) . The EC 50 of IVM for the Kir3.1-Kir3.2 heterotetramer was 3.5 ± 2.0 μM (n = 6); that for the Kir3.1-Kir3.4 heterotetramer was 7.5 ± 1.9 μM (n = 6) ( Fig. 1D ). The dose-response relationship was calculated from the ratio of the IVM-induced current (I IVM , the basal current was subtracted) to the basal current amplitude before the application of IVM (I Basal ) ( Fig. 1A-D ). In the presence of a saturated concentration of IVM (100 μM), the ratio of I IVM to I Basal (I IVM /I Basal ) of Kir3.1-Kir3.2 was 2.11 ± 0.43 (n = 6), whereas that of Kir3.1-Kir3.4 was 0.63 ± 0.21 (n = 6). The results show that IVM possesses a higher efficacy in the activation of Kir3.1-Kir3.2 than that of Kir3.1-Kir3.4. We also examined the effect of IVM on the Kir3.1-Kir3.3 heterotetramer and observed a negligible current in the presence or absence of IVM (Fig. 1E ). This is consistent with previous studies showing that expression of Kir3.3 reduces the activity of Kir3.3-Kir3.x heterotetramers (Kofuji et al. 1995; Lesage et al. 1995) . IVM-induced current was blocked by TPN-Q, a specific inhibitor of GIRK channel (Fig. 1F ). When we removed extracellular K + ions by replacing high K + solution (96 mM) with high Na + solution (96 mM), ion flux was eliminated at both -100 mV and 40 mV (Fig. 1G ). These results confirm that IVM activates GIRK channels and does not change the ion selectivity.
Avermectins activate Kir3.1-Kir3.2 current in Xenopus oocytes
IVM and its analogues are derived from avermectin, which was isolated from Streptomyces avermitilis. These 16-membered macrocyclic lactone derivatives, known as avermectins, have potent antiparasitic property and possess similar structures to IVM ( Fig. 2A ). Here we examined the effects of these avermectins on GIRK current in the same cell, using abamectin (ABM), doramectin (DOM), eprinomectin (EPM) and IVM. At 10 μM these avermectins activated GIRK current in oocytes expressing Kir3.1-Kir3.2, and ABM showed a similarly high efficacy to IVM ( Fig. 2B and C) . ABM, DOM and EPM possess low water solubility and they are only partially dissolved in DMSO; therefore in our experiments these drugs were fully dissolved in ethanol and diluted to a final solvent concentration <0.1% in the bath solution. Since ethanol is known to activate GIRK channels directly (Kobayashi et al. 1999) , we compared the effects of vehicle (0.1% ethanol) with ABM (10 μM) on GIRK activation in the same cell. We observed that application of vehicle induced a small increase in current amplitude and ABM-induced GIRK current was significantly larger than that of vehicle ( Fig. 2D and E). These results demonstrate that avermectins act as GIRK activators.
A previous study suggested that ABM formed hydrophobic pores in an artificial bilayer lipid membrane in a Teflon cell (Fomkina et al. 2001 ). Here we examined the effects of 10 μM ABM, DOM, EPM and IVM in 'blank' oocytes with no injection of cRNA. We observed that only ABM showed a negligible increase in current amplitude and the others showed almost no change in current amplitude (Fig. 2F ). Since the current amplitude of ABM-induced current in oocytes expressing Kir3.1-Kir3.2 was clearly larger than that of blank oocytes, we can exclude the contribution of an ion flux through the ABMformed pores in the plasma membrane of oocytes.
IVM activates native GIRK current in rat hippocampal neurons
Since we observed that IVM strongly activates Kir3.1-Kir3.2 using an in vitro expression system as shown in Fig. 1 , we next examined the effects of IVM on native GIRK current in neurons. Kir3.1-Kir3.2 heterotetramers are widely distributed in the brain, especially hippocampus, cerebral cortex and cerebellum (Liao et al. 1996) . Here we used cultured neurons of rat hippocampus for the measurement of native GIRK current. Whole-cell currents of hippocampal neurons were recorded by voltage clamp at a holding potential of -80 mV with a voltage ramp from -100 mV to 40 mV for 0.7 s, repeated every 2 s. A Ca 2+ -free high K + (25 mM) bath solution supplemented with TTX and ZD7288 was used to block the current through Na + channels, Ca 2+ -activated channels and hyperpolarization-activated cation current (I h ). Current-voltage (I-V) relationships of the basal neuronal current before (black traces) and after application of IVM (10 μM) without (red traces) or with TPN-Q (3 μM, blue traces) are shown in Fig. 3A and C, and the average of the reversal potential was -34.8 ± 7.8 mV (n = 7). Application of TPN-Q alone did not show a significant change in current amplitude of basal neuronal current. Application of 10 μM IVM increased the amplitude of the inward current ( Fig. 3A-D) . The IVM-induced current in hippocampal neurons (hippocampal I IVM ) was partially inhibited by 3 μM TPN-Q: TPN-Q inhibited 71.5% of hippocampal I IVM in Fig. 3A -B and 35.8% in Fig. 3C -D at -100 mV. The average of the hippocampal I IVM was 188.2 ± 122.3 pA (n = 7, shown in red) in the presence of IVM alone and 105.4 ± 115.2 pA (n = 7, shown in blue) in the presence of IVM and TPN-Q (Fig. 3E) . The presence of TPN-Q significantly decreased the current amplitude of hippocampal I IVM (normalized I was 0.49 ± 0.27 in the presence of IVM and TPN-Q, each n = 7, P = 0.003 in Fig. 3F ), suggesting that IVM activates native GIRK current in hippocampal neurons.
The partial block of the hippocampal I IVM by TPN-Q (Fig. 3A-F) may be due to an insufficient block of GIRK current by TPN-Q in the patched single neuron. Another possibility is that IVM activates not only GIRK channels in hippocampal neurons, but also an inward current via an unknown ion channel which is insensitive to TPN-Q.
IVM-mediated Kir3.1-Kir3.2 activation is independent of G βγ in Xenopus oocytes
Since the GIRK channel is known to be directly activated by G βγ subunits via the stimulation of GPCRs, here we examined the possibility that the effect of IVM is on the endogenous GPCR linked to the GIRK channel, using application of pertussis toxin (PTX), which uncouples G i/o from GPCRs and thereby prevents the activation of GIRK channels due to increased G βγ . In the oocytes co-expressing Kir3.1-Kir3.2 with M2 muscarinic receptor (M2R), pretreatment with PTX inhibited the M2R-mediated activation of GIRK current in the presence of the M2R agonist ACh (Fig. 4A) . However, pretreatment with PTX did not inhibit the IVM-induced GIRK current, suggesting that IVM-induced Kir3.1-Kir3.2 activation is independent of G i/o . To further confirm this finding, we examined the effect of IVM on a G βγ -insensitive mutant of Kir3.2. Leu344 in the βL-βM loop of the cytoplasmic domain of Kir3.2 is critical for G βγ binding (Whorton & MacKinnon, 2011 ) and a mutation of Leu344 to Glu (L344E) prevents G βγ -mediated activation of Kir3.2 (Finley et al. 2004) . In the oocytes co-expressing Kir3.2 L344E with M2R, we observed that L344E showed no response to the application of 1 μM ACh but it was sensitive to IVM (10 μM) (Fig. 4B) , showing that IVM-induced Kir3.2 activation is independent of G βγ . These results demonstrate that IVM directly activates GIRK channel without activating endogenous GPCRs or G-proteins in oocytes.
Single channel activity of Kir3.1-Kir3.2 in the presence of IVM in Xenopus oocytes
We also analysed the single channel behaviour of Kir3.1-Kir3.2 in the presence of IVM using cell-attached patch recording in oocytes. Single channel activity was recorded at a holding potential of -100 mV which showed transitions between the closed and open state in the absence (left) and presence (right) of 10 μM IVM (Fig. 5A) . Since there was no exogenous G βγ in the oocytes expressing Kir3.1-Kir3.2 alone, the single channel activity showed a few flickering openings between the long closures before applying IVM. After application of IVM to the bath solution, burst activities with longer open durations were observed. The open probability (NP open ) of Kir3.1-Kir3.2 was significantly increased by the application of IVM (NP open in the presence of IVM was 0.04 ± 0.02, n = 6, P = 0.008) (Fig. 5B) Since GIRK channel is modulated by PIP 2 , here we co-expressed Kir3.1-Kir3.2 with Ciona intestinalis voltage sensing phosphatase (Ci-VSP) (Murata et al. 2005) in oocytes to control endogenous PIP 2 levels. At highly depolarized potentials, the enzyme activity of subtracting the basal neuronal current from the current recorded in the presence of IVM. B and D, time courses of change in current amplitude ( I, the basal neuronal current was subtracted) in the absence and presence of IVM and TPN-Q at -100 mV. E, time courses of averaged I at -100 mV (n = 7 cells). F, normalized I induced by IVM in the absence (red symbols) and presence of TPN-Q (blue symbols). Current induced by IVM was normalized to 1. Each symbol shows raw data (from n = 7 cells) and some of the symbols overlap with each other. Each horizontal bar shows the mean of the group with error bars (SD). * Statistically significant difference (P < 0.05).
Ci-VSP increases, resulting in the dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ) and PIP 2 (Sakata et al. 2011) . We analysed the effect of the depolarization-dependent phosphatase activity of Ci-VSP on the co-expressed Kir3.1-Kir3.2 using various interval potentials (0, 10, 20, 40, 60, 80 mV) between each hyperpolarized test pulse (-100 mV) ( Fig. 6A and B) . The effect of depolarization-mediated activation of Ci-VSP reached a saturated level in terms of the reduction of GIRK current when the interval potential was higher than 60 mV, and the current recovered after changing the interval potential from a depolarized potential (80 mV) to resting potential (0 mV) ( Fig. 6B and C) . We also confirmed the Ci-VSP is indeed functional in our heterologous expression system by analysing the effect of depolarization-mediated activation of Ci-VSP on the channel activity of Kir2.1 (Fig. 6D) , which is known to possess a higher affinity for PIP 2 than Kir3.2 (Murata & Okamura, 2007) . IVM-induced GIRK current was almost eliminated by depolarization (60 mV)-mediated reduction in PIP 2 levels in the presence of Ci-VSP and not in the absence of Ci-VSP ( Fig. 6E and F) . Depolarization of the interval potential from 0 mV to 60 mV reduced 81.5 ± 5.1% (n = 5) of I IVM by Ci-VSP. A high concentration of wortmannin (a phosphoinositide 3-kinase and phosphoinositide 4-kinase inhibitor), which is commonly used to reduce PIP 2 production, reduced the response to IVM and prevented the recovery of GIRK current after changing the interval potential from a depolarized potential (60 mV) to resting potential (0 mV) (Fig. 6G) . These results show that IVM-mediated Kir3.1-Kir3.2 activation is dependent on PIP 2 . 
Identification of the structural determinants of Kir3.2 for IVM-mediated activation
Since Kir3.2 channels showed an especially remarkable response to IVM among GIRK subtypes (Fig. 1) , we speculated that some unique amino acid residue(s) in Kir3.2 channel may play important roles in IVM action (Fig. 7A) . Previous reports showed that IVM binds to the TMs of Cys-loop receptors and P2X 4 receptor (Silberberg et al. 2007; Lynagh & Lynch, 2012) , and therefore our foremost speculation was that the TMs of Kir3.2 also determine the IVM-mediated activation of GIRK channel.
To examine this hypothesis, we constructed chimeras between Kir3.2 and Kir3.4 by replacing various regions of Kir3.2 with those of Kir3.4 ( Fig. 7A and B) . These chimeric channels were functional when co-expressed with Kir3.1 in oocytes and showed responses to the application of 10 μM IVM (Fig. 7C) . Most of the chimeric channels showed similar I IVM /I Basal to wild-type (WT) Kir3.1-Kir3.2 (1.44 ± 0.43, n = 9), but only the chimera which possessed the N-terminal cytoplasmic segment of Kir3.4 showed a significant decrease (0.42 ± 0.13, n = 6, P = 0.008) and this was close to the I IVM /I Basa of Kir3.1-Kir3.4 (0.37 ± 0.08, n = 10). This suggests that the IVM effect is most likely modulated by the N-terminus region. The TMs, pore-forming region and C-terminal region of GIRK channel are not the primarily structural determinants for the IVM effect. Therefore, we next focused on the N-terminal region and constructed mutants by replacing the unique amino acid residues of Kir3.2 with those of Kir3.4 ( Fig. 7A and D) . Among these mutants, only the mutants containing the Ile82 to Leu (I82L) mutation showed a significant decrease in I IVM /I Basal in comparison to Kir3.2 WT (1.51 ± 0.46 for WT and 0.31 ± 0.04 for T80S and I82L, each n = 6, P = 0.002 in Fig. 7E ; 1.56 ± 0.34 for WT and 0.49 ± 0.10 for I82L, each n = 6-8, P < 0.001
in Fig. 7F) , showing that Ile82 of Kir3.2 is critical for the IVM-mediated GIRK activation. We also examined the mutant of a critical cysteine for dithiothreitol-dependent GIRK activation, C65A, and observed that Cys65 is not necessary for IVM-induced current increase (Fig. 7E) . In Kir3.4, mutation of Leu77 (a residue located at the same position as Ile82 in Kir3.2) to Ile (L77I) increased the response to IVM (I IVM /I Basal was 0.65 ± 0.23 for Kir3.4 WT; 1.53 ± 0.27 for L77I; 1.67 ± 0.46 for S75T and L77I, each n = 6-8 in Fig. 7F ), suggesting that the L77I mutation of Kir3.4 rescues the sensitivity to IVM compared with Kir3.4 WT. These results show that the Ile82 in Kir3.2 is indispensable for the IVM effect.
There is a possibility that the weak IVM effect of Kir3.2 I82L is due to a high basal activity of the channel. To examine this possibility, we analysed the GPCR-induced activation of this mutant in oocytes co-expressing Kir3.1-Kir3.2 I82L and M2R (Fig. 7G) . We observed that the 1 μM ACh-induced current (I ACh ) was much larger than the 10 μM IVM-induced current. The I ACh /I Basal was 1.42 and the I IVM /I Basal was 0.37, suggesting that Kir3.1-Kir3.2 I82L is still gated by G βγ /GPCR. The normal G βγ -gated property of Kir3.2 I82L is also consistent with that of Kir3.4 WT, in which a corresponding Leu is also located. The result shows that the weak IVM effect of Kir3.1-Kir3.2 I82L is not due to a high basal channel activity.
Roles of the branched side-chain of Ile82 of Kir3.2 in IVM-mediated activation
In the N-terminal region of Kir3.2, Ile82 locates in the slide helix between the TM1 and N-terminal CTDs (Figs 7A and 8A) (Whorton & MacKinnon, 2011) , and the amino acid residue at the corresponding position IVM. F, reduction of current amplitude from the level with 0 mV interval potential (as 100%) to that with 60 mV interval potential in oocytes without Ci-VSP (open symbols) and with Ci-VSP (filled symbols). Data show the raw data and the means ± SD, n = 6 cells for I Basal (circles); n = 5 for I IVM (triangles). Some symbols overlap with each other. G, pretreatment by 30 μM wortmannin for 1 h before recording prevented the recovery of GIRK current upon altering the interval potential from 60 mV to 0 mV in the presence of 10 μM IVM in oocytes expressing Kir3.1-Kir3.2 and Ci-VSP.
in Kir3.1, Kir3.3 and Kir3.4 is Leu. Ile82 of Kir3.2 is a branched side-chain amino acid with a methyl group towards the inner transmembrane helix (TM2), and this methyl group is lacking in the Leu77 of Kir3.4 (Fig. 8B  and C) . Therefore, we speculated that this methyl group on the branched side-chain is critical for IVM-mediated GIRK activation. To verify this hypothesis, we mutated Ile82 to Val (I82V), a branched side-chain amino acid with an inner methyl group, and compared the effect of IVM on I82V with other mutants at position 82, including mutations of Ile82 to Leu (I82L), Ala (I82A) and Trp (I82W) (Fig. 8D ). Co-expression of Kir3.1 with Kir3.2 I82V showed significantly larger I IVM /I Basal than those of I82L, I82A and I82W (1.29 ± 0.13 for I82V; 0.49 ± 0.10 for I82L; 0.36 ± 0.06 for I82A; 0.17 ± 0.05 for I82W, each n = 6, P < 0.001 for I82L, I82A and I82W when compared with I82V). These results support our speculation that the branched side-chain amino acid with a methyl group towards TM2 contributes to the IVM-dependent activation and that the large side-chain of Trp facing towards the outer side of the channel may disturb the rearrangement of TM-CTD interface upon IVM binding.
Roles of other amino acid residues surrounding Ile82 of Kir3.2
We further examined several mutants of amino acid residues surrounding Ile82 of Kir3.2 based on the Kir3.2 crystal structure (Whorton & MacKinnon, 2011) (Fig. 9A) . Mutations of Phe83 to Ala (F83A) and Phe186 to Trp (F186W) induced very little basal current which hindered the investigation of their roles in IVM effect. Mutations of Trp91 to Ala (W91A) and Ile195 to Ala (I195A) reduced the effects of IVM on GIRK current (I IVM /I Basal was 0.61 ± 0.08 for W91A; 0.26 ± 0.06 for I195A, each n = 6-7) and mutations of Leu86 to Ala (L86A) and Phe186 to Ala (F186A) showed no significant difference in I IVM /I Basal from that of WT (Fig. 9B) . The results show that Ile82 and Trp91 located in the slide helix and Ile195 located in the TM-CTD linker contribute to the IVM-mediated GIRK activation, presumably by forming part of the IVM-binding pocket in the TM-CTD interface (Fig. 9C ).
Discussion
The novel findings in the present study are as follows:
(1) IVM and its analogues act as GIRK activators in a PIP 2 -dependent manner and the IVM-mediated GIRK activation is independent of G βγ ; (2) IVM activates Kir3.2 more efficiently than Kir3.4; (3) IVM activates native GIRK current in hippocampal neurons; (4) a unique amino acid residue among GIRK family, Ile82, located in the slide helix between the TM1 and the N-terminal CTD of Kir3.2, is critical for the activation; (5) the methyl group of the branched side-chain of Ile82 towards TM2 acts as a switch for IVM-dependent activation; (6) Ile82 and Trp91 located in the slide helix and Ile195 located in the TM-CTD linker contribute to the IVM-dependent activation. The results demonstrate that the TM-CTD interface of Kir3.2 channels, rather than the TMs, acts as the structural determinant for IVM-mediated GIRK activation.
Insights into the roles of GIRK channel in the medication for parasitic infection
In the present study, we demonstrate that IVM and other avermectins activate GIRK channel (Kir3.1-Kir3.2 strongly and Kir3.1-Kir3.4 weakly) in a PIP 2 -dependent manner, and the IVM-mediated GIRK activation is independent of G βγ (Figs 1-6) . A recent study also showed the effect of IVM on the activation of the Kir3.2 homotetramer in HEK293 cells (Su et al. 2016) , but no detailed information was reported. We observed that the EC 50 of IVM for the activation of GIRK channel (Fig. 1D ) is similar to the ligand-gated channels of IVM targets in mammalian cells, such as the glycine receptor and GABA A R (1-10 μM) (Robertson, 1989; Schonrock & Bormann, 1993; Shan et al. 2001) , and this is much higher than the nanomolar concentration which activates the glutamate-gated Cl − channel in nematodes (Martin & Pennington, 1989; McCavera et al. 2009 ). However, adverse effects of IVM and other avermectins have been reported in several cases under medication for parasitic infection in humans and various animal species (Barragry, 1987; Lovell, 1990; Campbell, 1991) . Clinical trials in humans reported adverse effects of IVM in patients, including itching, oedema, dizziness and the Mazzotti reaction (Campbell, 1991) . Overdoses of IVM in some animal species that are hypersensitive to IVM, especially dogs, resulted in toxic symptoms, including listlessness, blindness, ataxia, bradycardia, depression, mydriasis, tremors, blindness, coma, and death in some cases (Barragry, 1987; Hopper et al. 2002) . A summarized report showed that the maximum plasma concentration of IVM in several animal species after drug administration was about 3-150 μM (calculated from ng ml −1 ), which depends on the species, route of administration, commercial formulation, body weight, physiological status and so on (Gonzalez Canga et al. 2009 ). This range of maximum plasma concentrations of IVM could be sufficient to influence GIRK channel activity in various organs. Since Kir3.1-Kir3.2 and Kir3.1-Kir3.4 heterotetramers are well known to regulate the excitability of neurons and the rate of heart beat, respectively (Noma & Trautwein, 1978; Krapivinsky et al. 1995; Liao et al. 1996; Inanobe et al. 1999; Hibino et al. 2010) , IVM-mediated activation of GIRK channel could contribute to some of the adverse effects, including the disorders of the central nervous system and bradycardia.
A unique action mode of IVM in GIRK channel
We showed that the Ile82 of Kir3.2 at the slide helix between the TM1 and the N-terminus CTD is the primary structural determinant for IVM-mediated GIRK activation, and the methyl group of the branched side-chain of Ile82 towards TM2 acts as a switch for IVM action (Figs 7-9 ). Here we considered two hypotheses to explain how the slide helix serves for IVM-dependent activation: (1) IVM binds to the slide helix and reinforces the hydrophobic core around the TM-CTD interface by forming novel hydrophobic interactions between IVM and Ile82/Trp91/Ile195, and thereby stabilizes the open state of channel (Meng et al. 2016) ; (2) IVM binds to another place and causes global conformational rearrangement of the channel, and this disturbs the hydrophobic interaction around the TM-CTD interface by forming novel hydrophobic interactions between the Ile82/Trp91/Ile195 and TM2 residues, thereby stabilizing the open state of channel (Meng et al. 2016) . Based on the results of chimera and point mutant experiments (Fig. 7) , it is most likely that, except for the unique Ile82 in Kir3.2, IVM does not bind to the amino acid residues which differ between Kir3.2 and Kir3.4. Therefore, we speculated that the Ile82 or the amino acid residues close to the TM-CTD interface could be the most likely potential binding site. Presumably Ile82 and Trp91 in the slide helix and Ile195 in the TM-CTD linker form part of the binding pocket for IVM (Fig. 9) . Since Trp91 and Ile195 are conserved in Kir3.2 and Kir3.4, the presence of these two residues could contribute to the weak response to IVM in Kir3. In Cys-loop receptors and the P2X 4 receptor, as shown through X-ray structure, mutagenesis and molecular modelling, IVM binds to the interface between two adjacent subunits in the TMs near the extracellular membrane surface (Silberberg et al. 2007; Jelinkova et al. 2008; Hibbs & Gouaux, 2011; Lynagh & Lynch, 2012; Zemkova et al. 2014; Du et al. 2015) . A Gly residue on the M3 helix of the Cys-loop receptor contributes to the high affinity for IVM binding, and some residues in the M1, M2 and M3 helices of TMs interact with IVM by forming an H-bond (Lynagh & Lynch, 2010 , 2012 Hibbs & Gouaux, 2011; Zemkova et al. 2014; Du et al. 2015) . The binding of two molecules of IVM is sufficient to activate Cys-loop receptors (Shan et al. 2001; Grudzinska et al. 2005; Lynagh & Lynch, 2010 , 2012 , and this is shared with the action mode of IVM in GIRK channels in which two of the structural determinant (Ile82) in the Kir3.1-Kir3.2 heterotetramers are sufficient to activate the channel.
Roles of PIP 2 in IVM-mediated GIRK activation
There are two functional gates in the GIRK channel, the inner helix gate and the G-loop gate, and they open and close rapidly during G-protein stimulation in the presence of PIP 2 (Nishida et al. 2007; Whorton & MacKinnon, 2011) . G-protein binds to the βL-βM loop of the CTD and only opens the G-loop gate; PIP 2 binds near the interface between TMs and CTDs but PIP 2 alone is insufficient to open each gate in the GIRK channel (Finley et al. 2004; Hansen et al. 2011; Whorton & MacKinnon, 2011 ). Since we observed that IVM could not activate GIRK channels in the absence of PIP 2 (Fig. 6) , we considered two possible reasons: (1) the binding of PIP 2 in GIRK channel causes a rotation of the slide helix (Whorton & MacKinnon, 2011) , allowing the approach of IVM to the Ile82. Thus, in the absence of PIP 2 , it is hard for IVM to be inserted into the TM-CTD interface; (2) the binding of IVM to GIRK opens only the G-loop gate in the absence of PIP 2 , and both gates can be opened in the presence of PIP 2 . Some studies have demonstrated that Lys64, Lys90, Arg92, Lys194, Lys199 and Lys200 in Kir3.2 contribute to PIP 2 binding (Hansen et al. 2011; Whorton & MacKinnon, 2011) . Since the critical residues for IVM-mediated GIRK activation, Trp91 and Ile195, are located just next to the PIP 2 -coordinating residues Lys90, Arg92 and Lys194, it is most likely that the association of PIP 2 with the GIRK channel induces stabilization of the TM-CTD interface, providing a suitable distance between the slide helix and the TM-CTD linker to receive IVM (Fig. 9C) .
In summary, our results have demonstrated the critical role of PIP 2 in the modulation of IVM-mediated GIRK activation and revealed the unique mode of action of IVM in the GIRK channel. The TM-CTD interface, rather than the TMs, acts as the structural determinant for IVM-mediated GIRK activation. The critical amino acid residue, Ile82 in the slide helix of Kir3.2, contributes to the high efficacy of the IVM response. This study provides novel insights into the mode of action of IVM in ion channels, and may also provide information that leads to identification of new pharmacophores which activate the GIRK channel.
